Clinically, blocking this event, namely the application of anti-PD-1 and anti-PD-L1 antibodies, could not only promote the proliferation of T cells but also restore the cytotoxic response of T cells to tumor cells [30, 34]. This evidence concerns the gene PDCD1 and neoplasm.